M. Masoli, D. Fabian, S. Holt, and R. Beasley, The global burden of asthma: executive summary of the GINA Dissemination Committee Report, Allergy, vol.59, issue.5, pp.469-478, 2004.

D. Sur, Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches, Nat Med, vol.18, issue.5, pp.716-741, 2012.

K. F. Chung, Targeting the interleukin pathway in the treatment of asthma, The Lancet, vol.386, issue.9998, pp.1086-1096, 2015.

G. G. Brusselle, T. Maes, and K. R. Bracke, Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma, Nature Medicine, vol.19, issue.8, pp.977-979, 2013.

J. Charriot, A. Gamez, M. Humbert, P. Chanez, and A. Bourdin, Thérapies ciblées dans l?asthme sévère : À la découverte de nouvelles molécules, Revue des Maladies Respiratoires, vol.30, issue.8, pp.613-626, 2013.

M. C. Mcgregor, J. G. Krings, P. Nair, and M. Castro, Role of Biologics in Asthma, American Journal of Respiratory and Critical Care Medicine, vol.199, issue.4, pp.433-445, 2019.

M. C. Mcgregor, J. G. Krings, P. Nair, and M. Castro, Role of Biologics in Asthma, American Journal of Respiratory and Critical Care Medicine, vol.199, issue.4, pp.433-445, 2019.

M. Delmas and C. Fuhrman, L?asthme en France : synthèse des données épidémiologiques descriptives, Revue des Maladies Respiratoires, vol.27, issue.2, pp.151-159, 2010.

C. Raherison, A. Bourdin, P. Bonniaud, G. Deslée, G. Garcia et al., Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de Pneumologie de Langue Française (SPLF) (Full length text), Revue des Maladies Respiratoires, vol.33, issue.4, pp.279-325, 2016.

P. Chanez, S. E. Wenzel, G. P. Anderson, J. M. Anto, E. H. Bel et al., Difficult-to-Treat Severe Asthma, GINA 2019 DIFFICULT-TO-TREAT & SEVERE ASTHMA in adolescent and adult patients, vol.119, pp.1337-1385, 2011.

P. Hekking, R. R. Wener, M. Amelink, A. H. Zwinderman, M. L. Bouvy et al., The prevalence of severe refractory asthma, Journal of Allergy and Clinical Immunology, vol.135, issue.4, pp.896-902, 2015.

R. G. Stirling and K. F. Chung, Severe asthma: definition and mechanisms, Allergy, vol.56, issue.9, pp.825-840, 2001.

M. Bloechliger, D. Reinau, J. Spoendlin, S. C. Chang, K. Kuhlbusch et al., P199 Adverse events profile of oral corticosteroids among asthma patients in the uk, External influences on asthma, 2017.

M. Bloechliger, D. Reinau, J. Spoendlin, S. Chang, K. Kuhlbusch et al., Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis, Respiratory Research, vol.19, issue.1, 2018.

D. Sur, inta, 07 ART7.pdf

D. Sur,

. Ct-16927_fasenra_ins_pic_avis2_ct16927, Benralizumab (Fasenra) for Severe Eosinophilic Asthma, JAMA, vol.319, issue.14, p.1501, 2018.

D. Sur,

. Ct-17909_dupixent_pic_ei_avis3_ct17909&17925_epi654, Informations sur la santé à l'intention des migrants: plate-forme internet migesplus, PrimaryCare, vol.9, issue.01, pp.16-18, 2009.

L. Pahus, K. Alagha, T. Sofalvi, I. Vachier, A. Bourdin et al., External Validity of Randomized Controlled Trials in Severe Asthma, American Journal of Respiratory and Critical Care Medicine, vol.192, issue.2, pp.259-261, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01763173

L. Pahus, D. Jaffuel, I. Vachier, A. Bourdin, C. M. Suehs et al., Randomised controlled trials in severe asthma: selection by phenotype or stereotype, European Respiratory Journal, vol.53, issue.2, p.1802187, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02061533

E. S. Harvey, D. Langton, C. Katelaris, S. Stevens, C. S. Farah et al., Mepolizumab effectiveness and identification of super-responders in severe asthma, European Respiratory Journal, vol.55, issue.5, p.1902420, 2020.

E. S. Harvey, D. Langton, C. Katelaris, S. Stevens, C. S. Farah et al., Mepolizumab effectiveness and identification of super-responders in severe asthma, European Respiratory Journal, vol.55, issue.5, p.1902420, 2020.

T. Numata, K. Nakayama, H. Utsumi, K. Kobayashi, H. Yanagisawa et al., Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis, BMC Pulmonary Medicine, vol.19, issue.1, p.176, 2019.

T. Numata, H. Miyagawa, H. Kawamoto, M. Yoshida, H. Utsumi et al., Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study, Cogent Medicine, vol.7, issue.1, 2020.

T. Numata, H. Miyagawa, H. Kawamoto, M. Yoshida, H. Utsumi et al., Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study, Cogent Medicine, vol.7, issue.1, p.1776468, 2020.

N. Dalkey, An experimental study of group opinion, Futures, vol.1, issue.5, pp.408-426, 1969.

D. Sur, Full Issue PDF Volume 40, Issue 11, Fisheries, vol.40, issue.11, pp.525-572, 2015.

D. Sur,

M. Humbert, F. C. Albers, D. J. Bratton, S. W. Yancey, M. C. Liu et al., Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility, Respiratory Medicine, vol.154, pp.69-75, 2019.

A. Magnan, A. Bourdin, C. M. Prazma, F. C. Albers, R. G. Price et al., Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1344, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01785638

A. Magnan, A. Bourdin, C. M. Prazma, F. C. Albers, R. G. Price et al., Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1344, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01785638

K. R. Chapman, F. C. Albers, B. Chipps, X. Muñoz, G. Devouassoux et al., The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma, Allergy, vol.74, issue.9, pp.1716-1726, 2019.

G. E. Carpagnano, C. Pelaia, M. D?amato, N. Crimi, N. Scichilone et al., Switching from omalizumab to mepolizumab: real-life experience from Southern Italy, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020.

G. E. Carpagnano, C. Pelaia, M. D?amato, N. Crimi, N. Scichilone et al., Switching from omalizumab to mepolizumab: real-life experience from Southern Italy, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020.

S. Liao, P. Sun, B. Li, S. He, M. Liu et al., A rare and fatal respiratory disease: bronchial Dieulafoy?s disease, Therapeutic Advances in Respiratory Disease, vol.14, p.175346662092923, 2020.

J. M. Fitzgerald, E. R. Bleecker, A. Menzies-gow, J. G. Zangrilli, P. Metcalfe et al., Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies, Airway Pharmacology and Treatment, 2017.

J. M. Fitzgerald, E. R. Bleecker, A. Menzies-gow, J. G. Zangrilli, I. Hirsch et al., Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies, The Lancet Respiratory Medicine, vol.6, issue.1, pp.51-64, 2018.

I. D. Pavord, S. Korn, P. Howarth, E. R. Bleecker, R. Buhl et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, The Lancet, vol.380, issue.9842, pp.651-659, 2012.

M. Mukherjee, F. Aleman, M. Kjarsgaard, K. Radford, N. Lavigne et al., Weight-adjusted Intravenous Reslizumab Attenuates Airway Eosinophilia in Severe Asthmatics compared to 100 mg Subcutaneous Mepolizumab, Monitoring Airway Disease, 2017.

M. Mukherjee, F. Aleman-paramo, M. Kjarsgaard, B. Salter, G. Nair et al., Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab, American Journal of Respiratory and Critical Care Medicine, vol.197, issue.1, pp.38-46, 2018.

E. R. Bleecker, M. E. Wechsler, J. M. Fitzgerald, A. Menzies-gow, Y. Wu et al., Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, European Respiratory Journal, vol.52, issue.4, p.1800936, 2018.

E. R. Bleecker, M. E. Wechsler, J. M. Fitzgerald, A. Menzies-gow, Y. Wu et al., Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, European Respiratory Journal, vol.52, issue.4, p.1800936, 2018.

H. G. Ortega, M. C. Liu, I. D. Pavord, G. G. Brusselle, J. M. Fitzgerald et al., Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma, New England Journal of Medicine, vol.371, issue.13, pp.1198-1207, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01785638

, Glucocorticoids and Mepolizumab in Eosinophilic Asthma, New England Journal of Medicine, vol.371, issue.25, pp.2433-2434, 2014.

C. Taillé, P. Chanez, G. Devouassoux, A. Didier, C. Pison et al., Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme, European Respiratory Journal, vol.55, issue.6, p.1902345, 2020.

M. Pichette, Les citoyens et les me?dias, 2006.

B. Brochet, Faut-il réaliser un suivi systématique par IRM chez les patients sous traitement de fond ?, Revue Neurologique, vol.169, p.A213, 2013.

V. Kocher, Compte rendu du colloque portant sur «l?intervention du juge dans le contrat», Europäisches Privatrecht in Vielfalt geeint - Droit privé européen: l'unité dans la diversité

, Taux de mortalité infantile, 2013.

, La croissance annuelle de la formation brute de capital fixe est inférieure au niveau de 2010 pour un tiers environ des pays de l?OCDE, 2020.

A. Laurent, J. Blanc, and G. Grangé, L?estomac est-il un critère de qualité majeur dans la coupe du périmètre abdominal ? Audit auprès de 3 opérateurs, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol.45, issue.5, pp.484-489, 2016.

, Graphique 13.4. La croissance annuelle de la formation brute de capital fixe est inférieure au niveau de 2010 pour un tiers environ des pays de l?OCDE

C. Jonas, Prévention du suicide: un dépistage aux urgences est possible, La Presse Médicale, vol.35, issue.5, pp.743-744, 2006.

, Graphique 6.20. Proportion des répondants qui estiment que la criminalité est un problème majeur dans leur pays (%), 2015

Y. Raibaud, Peut-on parler de musique noire ?, Volume !, issue.6 : 1-2, pp.171-175, 2008.
URL : https://hal.archives-ouvertes.fr/halshs-00335273

C. Galland, Les femmes travaillent quel que soit le prix, quel qu?en soit le prix, Genre et économie : un premier éclairage, pp.275-286